Anti-glypican 3 antibodies cause ADCC against human hepatocellular carcinoma cells-Reference-Cited by-同舟云学术

Anti-glypican 3 antibodies cause ADCC against human hepatocellular carcinoma cells

Published:2009-01 Issue:2 Volume:378 Page:279-284
ISSN:0006-291X
Container-title:Biochemical and Biophysical Research Communications
language:en
Short-container-title:Biochemical and Biophysical Research Communications

Author:

Nakano Kiyotaka,Orita Tetsuro,Nezu Junichi,Yoshino Takeshi,Ohizumi Iwao,Sugimoto Masamichi,Furugaki Koh,Kinoshita Yasuko,Ishiguro Takahiro,Hamakubo Takao,Kodama Tatsuhiko,Aburatani Hiroyuki,Yamada-Okabe Hisafumi,Tsuchiya Masayuki

Publisher

Elsevier BV

Subject

Cell Biology,Molecular Biology,Biochemistry,Biophysics

Reference20 articles.

1. Glypicans: proteoglycans with a surprise;Filmus;J. Clin. Invest.,2001

2. Mutations in GPC3, a glypican gene, cause the Simpson–Golabi–Behmel overgrowth syndrome;Pilia;Nat. Genet.,1996

3. Glypican-3-deficient mice exhibit developmental overgrowth and some of the abnormalities typical of Simpson–Golabi–Behmel syndrome;Cano-Gauci;J. Cell. Biol.,1999

4. OCI-5/GPC3. A glypican encoded by a gene that is mutated in the Simpson–Golabi–Behmel overgrowth syndrome, induces apoptosis in a cell line-specific manner;Gonzalez;J. Cell. Biol.,1998

5. Glypican-3 controls cellular responses to Bmp4 in limb patterning and skeletal development;Paine-Saunders;Dev. Biol.,2000

Cited by 99 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploring Glypican-3 as a Molecular Target in Hepatocellular Carcinoma: Perspectives on Diagnosis and Precision Immunotherapy Strategies;Frontiers in Bioscience-Landmark;2024-07-24

2. Cancer therapy with antibodies;Nature Reviews Cancer;2024-05-13

3. State of the Art in CAR-T Cell Therapy for Solid Tumors: Is There a Sweeter Future?;Cells;2024-04-23

4. SCD1 inhibition enhances the effector functions of CD8⁺ T cells via ACAT1‐dependent reduction of esterified cholesterol;Cancer Science;2023-10-25

5. GPC3-IL7-CCL19-CAR-T primes immune microenvironment reconstitution for hepatocellular carcinoma therapy;Cell Biology and Toxicology;2023-10-19